The role of vitamin D deficiency in hypertension development
https://doi.org/10.18705/1607-419X-2015-21-4-386-393
Abstract
Background. Increased renin-angiotensin-aldosterone system (RAAS) activity plays an important role in hypertension development. However, the associations between RAAS, hypertension and vitamin D status are not completely elucidated.
The aim of this study was to assess the role of vitamin D in hypertension development.
Design and methods. We studied blood pressure (BP), plasma aldosterone concentration (PAC) and plasma renin activity (PRA), PAC/PRA ratio, serum 25 (OH)D and parathyroid hormone (PTH) levels in 657 women aged between 30 and 55 years.
Results. We did not find differences in PAC, PRA and PAC/PRA ratio in women with hypertension and normal blood pressure level. The serum 25 (OH)D and PTH levels were comparable in hypertensive and normotensive women (48,95 ± 2,09 vs. 47,61 ± 1,03 nmol/l, p > 0,05, and 42,42 ± 2,76 vs. 40,68 ± 1,28 ng/ml, p > 0,05, respectively). A positive correlation between PTH level and PAC/PRA ratio (r = 0,25; p = 0,008) in normotensive subjects was found. There is a negative correlation between 25 (ОН)D level and PAC (r = –0,23, p = 0,01), PRA (r = 0,22, p = 0,02) in women with abdominal obesity, and a positive correlation between PTH level and PAC/PRA ratio (r = 0,51, p = 0,03) in non-obese women.
Conclusions. The results of this study demonstrate a possible role of vitamin D deficiency in hypertension development.
About the Authors
T. L. Karonova
V.A. Almazov Federal North-West Medical Research Centre;
First Pavlov State Medical University of St. Petersburg
Russian Federation
Russian Federation
MD, PhD, Head, Clinical Endocrinology Laboratory;
Associate Professor, Department of Therapy № 1 with the Course of Endocrinology, Cardiology and Functional Diagnostics n.a. G.F. Lang,
15 Parkhomenko avenue, St Petersburg, 197341
E. A. Bazhenova
First Pavlov State Medical University of St. Petersburg
Russian Federation
Russian Federation
MD, PhD, Assistant, Department of Therapy № 1 with the Course of Endocrinology, Cardiology and Functional Diagnostics n.a. G.F. Lang,
St Petersburg
O. D. Belyaeva
First Pavlov State Medical University of St. Petersburg
Russian Federation
Russian Federation
MD, PhD, Professor, Department of Therapy № 1 with the Course of Endocrinology, Cardiology and Functional Diagnostics n.a. G.F. Lang,
St PetersburgA. V. Berezina
V.A. Almazov Federal North-West Medical Research Centre
Russian Federation
Russian Federation
MD, PhD, Head of the Research Laboratory, Cardiopulmonary Exercise Testing,
St Petersburg
T. G. Ivanova
V.A. Almazov Federal North-West Medical Research Centre
Russian Federation
Russian Federation
MD, Laboratory Department,
St Petersburg
O. V. Galkina
First Pavlov State Medical University of St. Petersburg
Russian Federation
Russian Federation
MD, PhD, Head, Biochemical Homeostasis Laboratory Department,
St Petersburg
E. N. Grineva
V.A. Almazov Federal North-West Medical Research Centre;
First Pavlov State Medical University of St. Petersburg
Russian Federation
Russian Federation
MD, PhD, Professor, Director, Endocrinology Institute;
Professor, Department of Therapy № 1 with the Course of Endocrinology, Cardiology and Functional Diagnostics n.a. G.F. Lang,
St Petersburg
References
1. Pilz S, Tomaschitz A, Ritz E, Pieberet TR. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol. 2009;6(10):621–630.
2. Forman JP, Giovannucci E, Holmes MD, Bischoff-FerrariHA, Tworoger SS, Willett WC et al. Plasma 25‑hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49 (5):1063–1069.
3. Forman JP, Curhan GC, Taylor EN. Plasma 25‑hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52(5):828–832.
4. Porrecca E, Di Febbo C, Fusco L, Moretta V, Di Nisio M, Cuccurullo F. Solube thrombomodulin and vascular adhesion molecule-1 are associated to leptin plasma levels in obese women. Atherosclerosis. 2004;172(1):175–180.
5. Forouhi NG, Luan J, Cooper A, Boucer BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes. 57(10):2619–2625. doi: 10.2337/db08–0593.
6. Jorde R, Figenschau Y, Emaus N, Hutchinson M, Grimnes G. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but not predict future hypertension. Hypertension. 2010;55(3):792–798. doi: 10.1161/ HYPERTENSIONAHA. 109.143990.
7. Merke J, Hofmann W, Goldschmidt D, Ritz E. Demonstration of 1,25 (OH)2 vitamin D3 receptors and actionsin vascular smooth muscle cells in vitro. Calcif Tissue Int. 1987;41(2):112–114.
8. Somjen D, Weisman Y, Kohen F. 25‑hydroxyvitamin D3–1-alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation. 2005;111(11):1666–1671.
9. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–511. doi: 10.1161/CIRCULATIONAHA.107.706127
10. Motiwala SR, Wang TJ. Vitamin D and cardiovascular disease. Curr Opin Nephrol Hypertens. 2011;20(4):345–353.
11. Abu E, Maaty MA, Gad MZ. Vitamin d deficiency and cardiovascular disease: potential mechanisms and novel perspectives. J Nutr Sci Vitaminol (Tokyo). 2013;59(6):479–488.
12. Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25‑dihydroxyvitamin D3: specific inhibition at the level of messenger RNA. J Clin Invest. 1987;79(6):1659–1664.
13. O’Connell TD, Berry JE, Jarvis AK, Somerman MJ, Simpson RU. 1,25‑dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol. 1997;272 (4 Pt 2):1751–1758.
14. Li YC, Kong J, Wei MJ, Chen ZF, Liu SQ, Cao LP. 1,25‑dihydroxyvitamin D (3) is a negative endocrine regulator of renin-angiotensin system. Clin Invest. 2002;110(2):229–238.
15. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007; 369(9568):1208–1219.
16. Асташкин Е.И., Глезер М.Г. Новые данные о функционировании ренин-ангиотензиновой системы: роль внутриклеточной (интракринной) системы. Проблемы женского здоровья. 2012;7(4):47–54. [Astashkin EI, Glezer MG. New data about reninangiotensin system activity: the role of role intracellular (intracrine) system. Problems of women health. 2012;7(4):47–54. In Russian].
17. Bugress ED, Hawkins RG, Vatanabe M. Interaction of 1,25‑dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am J Hypertens. 1990;3:903–905.
18. Xiang W, Kong J., Chen S, Cao LP, Qiao G, Zheng W et al. Cardiac hypertrophy n vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288(1): E125–E132.
19. Kong J, Qiao G, Zhang Z, Liu SQ, Li YC. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int. 2008;74(12):1577–1581. doi: 10.1038/ki.2008.452.
20. Kristal-Bneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension. 1997;30(5):1289–1294.
21. Sowers M, Wallace R, Hollis B, Lemke JH. Relationship between 1,25‑dihydroxyvitamin D and blood pressure in a geographically defined population. Am J Clin Nutr. 1988;48 (4):1053–1056.
22. Schluter KD, Piper HM. Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol. 1992;263(6 Pt 2):1739–1746.
23. Perkovic V, Hewitson TD, Kelynack KJ, Martic M, Tait MG, Becker GJ. Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res. 2003;26 (1):27–33.
24. Martin-Ventura JL, Ortego M, Esbrit P, HernándezPresa MA, Ortega L, Egido J. Possible role of parathyroid hormone–related protein as a proinflammatory cytokine in atherosclerosis. Stroke. 2003;34(37):1783–1789.
25. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии иВсероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика. 2008;7(6):16. [Diagnosis and treatment of arterial hepertension. Recommendation of Russian medical society in arterial hypertension and all Russian science cardiology society. Cardiovascular therapy and prevention. 2008;7(6):16. In Russian].
26. 2013 European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2013;34(28):2159–2219.
27. IDF consensus worldwide definition of the metabolic syndrome: booklet [Electronic resource]/International Diabetes Federation. Worldwide definition of the metabolic syndrome, cop. 2006. Mode of access: Internet via World Wide Web. URL: http://www.idf.org/webdata/docs/IDF_Metasyndrome_difinition.pdf. Title from title screen. 24.
28. O’Seaghdla CM, Hwang SJ, Vasan RS, Larson MG, Hoffmann U, Wang TJ et al. Correlation of renin angiotensin and aldosterone system activity with subcutaneous and visceral adiposity: the Framingham Heart Study. BMC Endocr Disord. 2012;12(3):2–7. doi: 10.1186/1472–6823–12–3.
29. Holick MF. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine society clinical practice guideline. J Clin Metab. 2011;9:1911–1930.
30. Клинические рекомендации Российской ассоциации эндокринологов. Дефицит витамина D у взрослых: диагностика, лечение и профилактика. 2015. 75 c. URL: http://www.endocrincentr.ru/images/material-images/D %2019042014.pdf. [Clinical recommendations of Russian association of endocrinologists. Vitamin D deficiency in adults: diagnosis, treatment and prevention. 2015. 75 p. URL: http://www.endocrincentr.ru/images/material-images/D%2019042014.pdf].
31. Margolis KL, Martin LW, Ray RM, Kerby TJ, Allison MA, Curb JD et al. A prospective study of serum 25-hydroxyvitamin D levels, blood pressure, and incident hypertension in postmenopausal women. Am J Epidemiol. 2012;175(1):22–32. doi: 10.1093/aje/kwr274.
32. Ku YC, Liu ME, Ku CS, Liu TY, Lin SL. Relationship between vitamin D deficiency and cardiovascular disease. World J Cardiol. 2013;5(9):337–346. doi: 10.4330/wjc.v5.i9.337.
33. Баженова Е.А., Беляева О.Д., Березина А.В., Каронова Т.Л., Колодина Д.А., Бровин Д.Л. и др. Ренин-ангиотензин-альдостероновая система у больных абдоминальным ожирением и артериальной гипертензией. Артериальная гипертензия. 2013;9 (5):389–396. [Bazhenova EA, Belyaeva OD, Berezina AV, Karonova TL, Kolodina DA, Brovin DL et al. Renin-angiotensinaldolteron system in abdominal obese and hypertensive patients. Arterial Hypertension. 2013;19(5).389–396. In Russian].
34. Pilz S, Tomaschitz A, Marz W, Drechsler C, Ritz E, Zittermann A et al. Vitamin D, cardiovascular disease and mortality. Clinical Endocrinolgy. 2011;75(5):575–584. doi: 10.1111/j.1365–2265.2011.04147.x.
35. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86 (4):1633–1637.
36. Margolis KL, Ray RM, Van Horn L, Manson JE, Allison MA, Black HR et al. Effect of calcium and vitamin d supplementation on blood pressure: the Women’s Health Initiative Randomized Trial. Hypertension. 2008;52(5):847–855. doi: 10.1161/HYPERTENSIONAHA.108.114991.
37. Withman MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens. 2009;27(10):1948–1954. doi: 10.1097/HJH.0b013e32832f075b.
Review
For citations:
Karonova T.L., Bazhenova E.A., Belyaeva O.D., Berezina A.V., Ivanova T.G., Galkina O.V., Grineva E.N. The role of vitamin D deficiency in hypertension development. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2015;21(4):386-393. (In Russ.) https://doi.org/10.18705/1607-419X-2015-21-4-386-393
Views:
1519
Email this article 